Planning

Qualified Person Service for Investigational Medicinal Product (IMP)

  • NHS Blood and Transplant

F01: Prior information notice (prior information only)

Notice identifier: 2023/S 000-022326

Procurement identifier (OCID): ocds-h6vhtk-03ec0d

Published 1 August 2023, 1:38pm



Section one: Contracting authority

one.1) Name and addresses

NHS Blood and Transplant

500 North Bristol Park

Bristol

BS34 7QH

Contact

Richard Athay-Hunt

Email

richard.athay-hunt@nhsbt.nhs.uk

Country

United Kingdom

Region code

UKK11 - Bristol, City of

Internet address(es)

Main address

https://www.nhsbt.nhs.uk/

Buyer's address

https://www.nhsbt.nhs.uk/

one.3) Communication

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

https://health-family.force.com/s/Welcome

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Health


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Qualified Person Service for Investigational Medicinal Product (IMP)

Reference number

C197288

two.1.2) Main CPV code

  • 73100000 - Research and experimental development services

two.1.3) Type of contract

Services

two.1.4) Short description

NHSBT are looking to appoint a suitable Qualified Person (QP) on a contract basis to work alongside its existing in-house QPs to support a very active and rapidly growing portfolio of Investigational Medicinal Product (IMP) manufacturing projects.

two.1.5) Estimated total value

Value excluding VAT: £260,000

two.1.6) Information about lots

This contract is divided into lots: No

two.2) Description

two.2.3) Place of performance

NUTS codes
  • UKK1 - Gloucestershire, Wiltshire and Bristol/Bath area

two.2.4) Description of the procurement

NHSBT are looking to appoint a suitable Qualified Person (QP) on a contract basis to work alongside its existing in-house QPs to support a very active and rapidly growing portfolio of Investigational Medicinal Product (IMP) manufacturing projects.
NHSBT has developed the capability over at least 20 years to manufacture a range of Biotechnology, Gene Therapy, Cell Therapy and Tissue Engineered Medicinal Products for Phase I/II clinical Trials. Many of these are categorised as Advanced Therapy Medicinal Products (ATMP) in accordance with EU Regulations. IMP manufacture is focused at NHSBT facilities in Barnsley, Bristol, Birmingham, and Liverpool holding appropriate MIA(IMP). NHSBT manufacture IMP for both internally sponsored Clinical Trials and under contract for academic and commercial clients.

The services we require the Qualified Person (QP) to support are as follows:

· Advice on regulatory and quality compliance requirements for specific Biological and ATMP manufacturing projects.

· Input to selected regulatory submissions

· Input to design of selected processes and facilities

· QP Certification of batches of biological & ATMP for use in approved clinical trials

· Mentoring of selected NHSBT staff through the process of obtaining QP registration

two.3) Estimated date of publication of contract notice

20 September 2023


Section four. Procedure

four.1) Description

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No